Fibrinolysin clinical trials
Also written Plasmin, TAL-05-00018 and BAY-57-9602.
How each study uses Fibrinolysin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Fibrinolysin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 1 Apr 1964 · ELASE-CHLOROMYCETIN · BLA 050294 (FDA, Drugs@FDA; in a combination)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Grifols Therapeutics LLC (3) · Bausch & Lomb Incorporated (2) · Christian Haslinger (1)
Related medicines
As reviewed, each with the page that says it.
- One of Thrombolytics source
Studies
Open first, then newest update. How each study uses Fibrinolysin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- SWIFT - SWIss Factor XIII Trial in PPHRecruitingPhase 4Christian HaslingerNCT06481995Written as FibrogamminHow we know
- A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)TerminatedPhase 1/2Bausch & Lomb IncorporatedNCT00347646Written as PlasminHow we know
- Study to Evaluate Plasmin for the Creation of a Posterior Vitreous DetachmentTerminatedPhase 2Bausch & Lomb IncorporatedNCT00348439Written as PlasminHow we know
- A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial OcclusionCompletedPhase 2Grifols Therapeutics LLCNCT01222117Written as PlasminHow we know
- A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft OcclusionCompletedPhase 1Grifols Therapeutics LLCNCT00418483Written as Plasmin (Human) 25 mgHow we know
- A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke PatientsCompletedPhase 1/2Grifols Therapeutics LLCNCT01014975Written as Plasmin (Human)How we know
Codes
What other systems call Fibrinolysin · ClinicalTrials.gg INT007489
- MeSH (NLM) D005341FibrinolysinOne source ClinicalTrials.gov
- UNII (FDA) D60E3WIF5YFIBRINOLYSIN (HUMAN)One source FDA
- RxNorm 4388One source FDA
- NCI Thesaurus C180643Fibrinolysin HumanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005341 | Fibrinolysin | One source ClinicalTrials.gov |
| UNII (FDA) | D60E3WIF5Y | FIBRINOLYSIN (HUMAN) | One source FDA |
| RxNorm | 4388 | — | One source FDA |
| NCI Thesaurus | C180643 | Fibrinolysin Human | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.